ArticleJournal of cancer research and clinical oncology2021

Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers.

Dorothea Hose et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.